FindTrial
Sign In

Citrate and Bivalirudin as anticoagulation agent in Continuous Renal Replacement Therapy (CRRT)

A Study of Citrate and Bivalirudin for anticoagulation during Continuous Renal Replacement Therapy (CRRT) in Critically ill Patients with Acute kidney Injury (AKI)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/02/031419
Enrollment
40
Registered
2021-02-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N179- Acute kidney failure, unspecified

Interventions

None listed

Sponsors

DR RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Severe AKI (KDIGO 3 classification) despite optimal resuscitation -Urine output of less than 0.3 mL/Kg/hour for 24 hours or more than 24 hours. -Less than threefold increase in serum creatinine level compared with baseline valve -Serum creatinine 4.0 mg/dl or more than 4.0 mg/dl. 2.Minimum 3 fold increase in Serum Creatinine level along with clinical decision by clinician. 3.Intention to provide full intensive care treatment for at least 3 day. 4.Written informed consent of patient or his legal representatives or the Authorized Representative. 5.Inclusion due to an emergency situation.

Exclusion criteria

Exclusion criteria: 1.Declined consent from guardian. 2.Patients with an increased bleeding risk (or) active bleeding due to vascular damage (Ulcer in G.I. tract, Intracranial Hemorrhage, Aneurysm of brain arteries). 3.Dialysis-dependent chronic kidney insufficiency. 4.Allergic reaction to one of the anticoagulants. 5.Need of therapeutic anticoagulation ( aPTT >60s, anti-Xa >0.6IE/mL, INR >2) 6.AKI caused by Glomerulonephritis, Interstitial Nephritis, Vasculitis or Urinary Tract Obstruction. 7.Haemolytic Uraemic Syndrome/ Thrombotic Thrombocytopenic Purpura. 8.Kidney transplant within the last 12 months. 9.Pregnancy and Nursing period.

Design outcomes

Primary

MeasureTime frame
To study the filter life span using Citrate and Bivalirudin as anticoagulation agent in CRRT.Timepoint: Every 1 hourly from initiation of CRRT to completion of CRRT.—

Secondary

MeasureTime frame
1.To study the length of stay in ICU. 2.To study the bleeding and other complication of CRRT. 3.To study the transfusion requirement. Timepoint: 1- Every 24 hourly after get admitted in ICU till get discharged (For Length of stay in ICU) 2- After 1 hour of completion of CRRT. ( For Transfusion requirement, bleeding and other complications of CRRT).—

Countries

India

Contacts

Public ContactDR DEEPAK YADAVA

DR RAM MANOHAR LOHIA INSTITUTE OF MEDICAL SCIENCES

drdm58@gmail.com05226692063

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026